Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01325441 · ClinicalTrials.gov registry record · Phase 1
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
A Phase 1 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 1
- Development phase
- 565
- Enrollment target
NCT01325441 is a Phase 1 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 565 participants.
The verdict
NCT01325441, a Phase 1 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 565 participants
- Enrollment target
Study Summary
This is an open label, single arm phase 1 dose escalation study and phase 2 study of BBI608 in combination with paclitaxel in patients with advanced malignancies.
Interventions
- DRUG Paclitaxel
- DRUG BBI608
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 565 participants |
| Start Date | 2011-04 |
| Est. Completion | 2021-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01325441
The ClinicalTrials.gov registry entry for NCT01325441 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 565 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Paclitaxel is the first listed.
NCT01325441 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01325441 about?
NCT01325441 is a clinical study titled "A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies". This is an open label, single arm phase 1 dose escalation study and phase 2 study of BBI608 in combination with paclitaxel in patients with advanced malignancies.
What is the current status of trial NCT01325441?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 565 participants. The study started on 2011-04. Estimated completion is 2021-06-01.
What interventions are being tested in trial NCT01325441?
The interventions under investigation include: Paclitaxel (DRUG), BBI608 (DRUG).
Who is sponsoring clinical trial NCT01325441?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.